Victoria Socha

DocwireNews

NKF 2021 Spring Clinical MeetingsMore than one third of patients in the United States receiving dialysis are Black or African American. The leading cause of kidney failure in that patient population is diabetes. Results of the FIDELIO-DKD trial of finerenone demonstrated a reduction in risk of progression of chronic kidney disease in patients with CKD and type 2 diabetes treated with finerenone.During a virtual poster session at the NKF Spring Clinical Meetings 2021, George Bakris, MD, and colleagues reported results of an analysis of data from FIDELIO-DKD on outcomes among Black or African American patients. The <a href="https://casehippo.com/spa/symposium/national-kidney-foundation-2021-spring-clinical-meetings/event/gallery/abstracts?abstractId=1922">poster</a> was titled Impact of Finerenone on Chronic Kidney Disease Progression in Black or African American Patients with Type 2 Diabetes&mdash;Analysis of the FIDELIO-DKD Study.The study randomized 5734 patients from 48 countries to receive either oral finerenone or placebo. Inclusion criteria were type 2 diabetes, urine albumin-creatinine ratio (UACR) 30-5000 mg/g, estimated glomerular filtration rate (eGFR) 25-&lt;75 mL/min/1.73 m2, and treatment with optimized renin-angiotensin system blockade. The primary renal outcomes of interest was time to kidney failure, sustained decline in eGFR &ge;40% from baseline, or renal death. Prespecified secondary outcomes were time to kidney failure, sustained eGFR decline 57% from baseline or renal death, and change in UACR from baseline to month 4.Of the overall cohort, 4.7% (n=264) were Black or African American. Of those, 76.5% were from North America. Median follow-up was 2.6 years.Compared with White or Asian patients, the risk of kidney failure outcomes was <a href="https://www.docwirenews.com/urban-health-today/urban-health-picks/study-finds-health-disparities-in-black-men-with-prostate-cancer/">higher</a> in Black patients. In the subgroup of Black patients, the incidence rate of the primary kidney outcome was lower in the finerenone group than in the placebo group (13.9/100 patient years vs 17.2/100 patient years; hazard ratio [HR], 0.78; 95% confidence interval [CI], 0.51-1.19, respectively). The incidence rate for the secondary kidney outcome was also lower in Black patients in the finerenone group compared with the placebo group (HR, 0.76; 95% CI, 0.45-1.28). At month 4, UACR was reduced by 33% (95% CI, 43%-21%) in Black patients treated with finerenone compared with placebo.There was no evidence of heterogeneity between Black or African American patients and other racial/ethnic groups for the kidney outcomes analyzed. In the subgroup of Black or African American patients, treatment-emergent adverse events and serious adverse events were balanced between the finerenone group and the placebo group.In conclusion, the researchers said, &ldquo;In FIDELIO-DKD there was a trend toward reducing kidney outcomes in the small subset of Black patients included in the trial.&rdquo;Source: Bakris G, Joseph A, Anker S, et al. Impact of finerenone on chronic kidney disease progression in Black or African American patients with type 2 diabetes&mdash;analysis of the FIDELIO-DKD study. Abstract of a poster presented at the National Kidney Foundation virtual Spring Clinical Meetings 2021 (Abstract #254), April 9, 2021. FIDELIO-DKD was funded by Bayer AG (NCT02540993).

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Renal Outcomes in FIDELIO-DKD Trial in Subset of Black Patients

Part of NephTimes Diseases and Conditions

Diabetes and Hypertension

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe